25.96 0.00 (0.00%)
After hours: 4:44PM EDT
|Bid||25.97 x 900|
|Ask||26.10 x 1000|
|Day's Range||25.45 - 26.10|
|52 Week Range||12.77 - 28.67|
|Beta (3Y Monthly)||2.34|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Yahoo Finance's Adam Shapiro, Julie Hyman, Jessica Smith, and Brian Sozzi discuss the Pharma executives testifying in the Senate drug price hearings.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACADView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for ACAD with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACAD are favorable, with net inflows of $2.89 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Acadia (ACAD) delivered earnings and revenue surprises of -9.26% and 6.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 59 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]
Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While it may not be enough for some shareholders, we think it is good to see the ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) share price up 12% in a single quarter. But that doesn't change the fact that the returns over the last...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 27) Baxter International Inc (NYSE: BAX ) Catalyst Pharmaceuticals ...
Mid-caps stocks, like ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a market capitalization of US$3.8b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
Fourth-quarter earnings season is winding down. It disclosed encouraging Phase 2 data for Nuplazid to treat major depressive disorder in October and will start two Phase 3 studies for that indication later this year.
Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.